Cytokinetics (NASDAQ: CYTK) R&D chief sells 3,500 shares in 10b5-1 trade
Rhea-AI Filing Summary
CYTOKINETICS INC (CYTK) executive Fady Ibraham Malik, EVP Research & Development, reported an option exercise-and-sell transaction. On 2026-08-18 he exercised 3,500 non-qualified stock options at an exercise price of $7.80 per share, acquiring 3,500 shares of common stock, and on the same date sold 3,500 common shares at $75.82 per share. Following the option exercise, he held 30,386 options of this grant directly. The transactions were affirmed as made pursuant to a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,500 shares ($238K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Malik Fady Ibraham
Role
EVP Research & Development
Sold
3,500 shs ($265K)
Approx. gross sale proceeds
$265K
Approx. exercise cost
$27K
Approx. pre-tax spread
$238K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 3,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,500 | $7.80 | $27K |
| Sale | Common Stock | 3,500 | $75.82 | $265K |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 30,386 shares (Direct);
Common Stock — 153,902 shares (Direct)
Key Figures
Options Exercised: 3,500 shares
Option Exercise Price: $7.80 per share
Shares Sold: 3,500 shares
+3 more
6 metrics
Options Exercised
3,500 shares
Non-Qualified Stock Option (Right to Buy) exercised on 2026-08-18
Option Exercise Price
$7.80 per share
Conversion or exercise price of non-qualified stock options
Shares Sold
3,500 shares
CYTOKINETICS common stock sold on 2026-08-18
Sale Price
$75.82 per share
Price for CYTOKINETICS common stock sale transaction
Options Remaining
30,386 options
Non-qualified stock options held directly after the exercise
Net Share Change
-3,500 shares
Net buy/sell shares across reported non-derivative transactions
Key Terms
Non-Qualified Stock Option (Right to Buy), derivative security, Rule 10b5-1
3 terms
Non-Qualified Stock Option (Right to Buy) financial
"security_title: Non-Qualified Stock Option (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Rule 10b5-1 regulatory
"aff_10b5_one true indicates a Rule 10b5-1 trading plan"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
What insider transaction did CYTK EVP Fady Malik report on this Form 4?
Fady Malik reported an exercise and sale on 2026-08-18, exercising 3,500 options for CYTOKINETICS (CYTK) shares at $7.80 and selling 3,500 common shares at $75.82 the same day.
How many CYTK options did Fady Malik exercise and at what price?
He exercised 3,500 non-qualified stock options at an exercise price of $7.80 per share. These options were originally exercisable starting 2018-03-27 and are scheduled to expire on 2028-02-27.
At what price did Fady Malik sell CYTOKINETICS (CYTK) common stock?
He sold 3,500 CYTK common shares at a price of $75.82 per share on 2026-08-18. The sale followed his same-day exercise of 3,500 stock options into common stock.
How many CYTK options does Fady Malik hold after this transaction?
After exercising 3,500 options, he held 30,386 non-qualified stock options of this grant directly. This figure reflects the remaining derivative position reported for that specific option award following the transaction.
Were Fady Malik’s CYTK trades made under a Rule 10b5-1 plan?
Yes. The filing indicates the trades were made under a Rule 10b5-1 trading plan. Such pre-arranged plans allow insiders to schedule trades in advance, which can reduce the informational significance of trade timing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
